Recida Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Recida Therapeutics, Inc. - overview
Established
2016
Location
Menlo Park, CA, US
Primary Industry
Pharmaceuticals
About
Founded in 2016 and based in California, US, Recida Therapeutics, Inc. is a biopharmaceutical company that develops anti-infective medicines for multi-drug resistant infections. The company's program RC-01, an IND-stage LpxC inhibitor to treat multidrug-resistant gram-negative infections. RC-01 prevents bacterial LpxC, an enzyme in Lipid A biosynthesis, which is an essential component of the outer membrane of gram-negative bacteria for its survival.
Current Investors
CARB-X, Frazier Healthcare Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.recidatherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.